Serial Endoscopic Surveillance & Direct Topical Antibiotics to Define the Role of Microbes in Anastomotic Healing (SES-DTA)
Anastomotic Leak, Rectal Cancer
About this trial
This is an interventional prevention trial for Anastomotic Leak focused on measuring Rectal Cancer, low anterior resection, SES, SES-DTA, anastomotic leak, anastomotic healing, intestinal healing, anastomosis
Eligibility Criteria
Inclusion Criteria
- Diagnosis of rectal cancer
- Scheduled to undergo a low anterior resection (with the planned anastomosis within 10cm of the anal verge) and a diverting ileostomy
- 18 years of age or older
- Able to provide informed consent
Exclusion Criteria
- Prior medical history of or suspected diagnosis of inflammatory bowel disease or irritable bowel syndrome
- Pregnant or breastfeeding
- Allergy to lidocaine, ciprofloxacin, metronidazole or neomycin
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
Cipro, metronidazole, neomycin combo
Saline
As part of each serial endoscopic surveillance, a second lavage of the anastomosis will be performed prior to removing the endoscope. In this arm, the lavage will be with a direct topical antibiotics solution composed of metronidazole, ciprofloxacin and neomycin.
As part of each serial endoscopic surveillance, a second lavage of the anastomosis will be performed prior to removing the endoscope. In this arm, the lavage will be with direct topical saline.